CME Group Inc. (CME) Down 4.7% — Should I Harvest This Position?
CME Group Inc. (CME) gave back a meaningful chunk of its recent gains on Tuesday, closing at $293.48 on the NASDAQ — a $14.58 decline from the prior close of $308.06. The drop leaves the stock roughly 10.8% below its 52-week high of $329.16, set on March 3, 2026. The exchange operator had been working its way back toward that level over the past two weeks, and Tuesday's session erased about half of that progress in a single day.
Volume came in at roughly 1.75 million shares, well below the 90-day average of about 2.44 million. The selling was sharp in price terms but light in participation, with turnover running at roughly 72% of normal.
Why CME Group Inc. Price is Moving Lower
The decline was specific to CME. The S&P 500 rose 0.6%, the Nasdaq gained 1.2%, and the Banking & Investment Services group was up 0.24% today. Big Financials names moved the other way, with Morgan Stanley (MS) up 1.86% and BlackRock (BLK) up 0.74%. With the broader tape supportive, the most plausible explanation is profit-taking and a valuation reset after a quick run. CME closed at $285.59 on October 14 and climbed to $308.06 by October 26, a gain of about 7.9% in under two weeks. Tuesday's drop unwound much of that advance.
That run-up was built on a solid quarter. On October 21, CME reported Q3 revenue of $1.737 billion, ahead of the roughly $1.71 billion to $1.72 billion consensus and up 13% year over year. Adjusted EPS came in at $3.02 against expectations of $2.98 to $2.99, up 13% from $2.68 a year earlier. Average daily volume reached a record 29.4 million contracts, up 16%. The beat was clean, but it was not dramatic, and a stock trading at a forward P/E of 25.27 leaves little room for further multiple expansion once the good news is priced in.
A competitive question also hangs over the name. On October 16, the CFTC argued that CME's lawsuit over Kalshi's Bitcoin perpetual contract should be dismissed because CME had not shown concrete harm. That dispute predates Tuesday's selling. Still, it keeps attention on the growing number of venues competing for derivatives activity, and it gives investors one more reason to lock in gains after a strong two-week stretch.
What is the CME Group Inc. Rating - Should I Sell?
Weiss Ratings assigns CME a B rating. Current recommendation is Buy. A single-day pullback after a profit-taking surge does not change the underlying picture. The rating reflects a business with exceptional economics, though the price action shows that even high-quality names are not immune to sharp swings.
CME's fundamentals carry the rating. The Excellent rating on the Growth Index is backed by 12.96% revenue growth, a strong pace for an exchange operator of this scale. The record 29.4 million contracts in average daily volume last quarter shows that growth comes from rising trading activity rather than one-time items. The Excellent Efficiency Index rating reflects a 63.48% profit margin, which captures how much incremental volume falls straight to the bottom line once the clearing and trading infrastructure is in place. The 16.13% ROE confirms that profitability in return terms. An Excellent rating on the Solvency Index adds balance sheet strength to that picture. A Good rating on the Dividend Index fits a 3.67% yield supported by $12.19 in trailing EPS, a combination that income-focused holders will find hard to match elsewhere among exchange operators.
Where the picture becomes more nuanced is in the market-facing indices. The Good rating on the Total Return Index reflects solid but not standout results for shareholders. The stock still sits about 10.8% below its March high despite record quarterly results. The Fair rating on the Volatility Index illustrates why that dimension is not rated higher. A 4.73% drop on a day when the S&P 500 and Nasdaq both advanced shows how quickly sentiment can swing after a short-term run-up, even for a company with steady earnings.
Within the Financials sector, CME sits alongside MasterCard Incorporated (MA, B) and Morgan Stanley (MS, B). It trails Visa Inc. (V, B+) and sits ahead of American Express Company (AXP, B-) and BlackRock, Inc. (BLK, B-). That positioning puts CME among the stronger names in its sector by Weiss's measure, even after Tuesday's decline.
About CME Group Inc.
CME Group Inc. (CME) is a Financials companythat runs one of the world's largest derivatives marketplaces. Headquartered in Chicago, the company operates four major exchanges: the Chicago Mercantile Exchange, the Chicago Board of Trade, the New York Mercantile Exchange, and COMEX. Together they offer futures and options across nearly every major asset class. Its flagship contracts include SOFR and U.S. Treasury futures in interest rates, E-mini S&P 500 and Nasdaq-100 futures in equity indexes, WTI crude oil and natural gas in energy, and gold and silver in metals. The company also lists corn, soybean, and wheat contracts in agriculture, alongside foreign exchange and bitcoin and ether futures.
Revenue comes mainly from clearing and transaction fees tied to contract volume. CME supplements that with market data subscriptions and fees from its cash and over-the-counter businesses, including BrokerTec for U.S. Treasury trading and EBS for foreign exchange. CME Clearing sits at the center of the model, acting as the central counterparty for trades across its venues. That role gives the company a direct stake in nearly every transaction while strengthening the network effects that keep liquidity concentrated on its platforms.
That liquidity is CME's most durable competitive advantage. Deep order books in benchmark contracts attract institutional hedgers, asset managers, and proprietary traders, and their activity in turn deepens the books further. Rivals find that cycle difficult to break. Periods of market volatility, shifting interest rate expectations, and energy price swings tend to drive hedging demand, which helps support volumes across economic cycles. The company still faces ongoing competition from alternative venues and new contract structures, as well as regulatory decisions that shape how derivatives markets evolve.
Investor Outlook
CME Group Inc. (CME) carries a Weiss Rating of B (Buy), and Tuesday's decline looks more like a valuation reset after a 7.9% two-week climb than a break in the fundamental story. Investors should watch whether monthly average daily volume holds near the record 29.4 million contracts posted in the third quarter, and how the Kalshi dispute and broader competition from new derivatives venues develop in the months ahead. See full rankings of all B-rated Financials stocks inside the Weiss Stock Screener.
--